TickerFacts.

Company research / BIIB

Biogen Inc. (BIIB)

Build a valuation ↗↓ Download CSV

SEC name BIOGEN INC. · CIK 0000875045 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Biogen Inc. reported revenue of $9.89B. Revenue grew 2.2% from the prior annual period. Over the twelve months to 2026-03-31, revenue was $9.94B.

Key ratios (year ended 2025-12-31)

75.7%
Gross margin (computed)
13.1%
Net margin
7.1%
Return on year-end equity
2.2%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-05

Headquarters locality: Cambridge · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-03-31 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-03-31		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$9.94B$9.89B$9.68B$9.84B$10.17B$10.98B$13.44B$14.38B$13.45B$12.27B$11.45B
Cost of Revenue$2.44B$2.40B$2.31B$2.53B$2.28B$2.11B$1.81B$1.96B$1.82B$1.63B$1.48B
Gross Profit$7.50B$7.49B$7.37B$7.30B$7.90B$8.87B$11.64B$12.42B$11.64B$10.64B$9.97B
R&D Expense$1.88B$1.78B$1.98B$2.45B$2.23B$2.50B$3.99B$2.28B$2.60B$2.25B$1.97B
Operating Incomen/an/an/an/an/a$2.84B$4.55B$7.04B$5.89B$5.35B$5.15B
Depreciation & Amortization$801.10M$779.90M$673.20M$494.80M$518.40M$487.70M$457.20M$464.70M$650.50M$1.08B$682.70M
EBITDAn/an/an/an/an/a$3.33B$5.01B$7.51B$6.54B$6.43B$5.83B
Net Income$1.37B$1.29B$1.63B$1.16B$3.05B$1.56B$4.00B$5.89B$4.43B$2.54B$3.70B
EPS (Diluted)n/a$8.79$11.18$7.97$20.87$10.40$24.80$31.42$21.58$11.92$16.93
Total Assets$29.48B$29.44B$28.05B$26.84B$24.55B$23.88B$24.62B$27.23B$25.29B$23.65B$22.88B
Total Liabilities$10.83B$11.18B$11.33B$12.05B$11.17B$12.92B$13.93B$13.90B$12.26B$11.05B$10.75B
Long-Term Debt$6.29B$6.29B$6.30B$6.94B$6.28B$6.27B$7.43B$4.46B$5.94B$5.93B$6.51B
Shareholders' Equity$18.65B$18.26B$16.72B$14.80B$13.39B$10.96B$10.69B$13.34B$13.03B$12.60B$12.13B
Cash & Equivalentsn/an/an/an/an/an/an/a$2.91B$1.22B$1.57B$2.33B
Operating Cash Flow$2.59B$2.20B$2.88B$1.55B$1.38B$3.64B$4.23B$7.08B$6.19B$4.55B$4.59B
Capital Expenditures$167.90M$153.80M$153.70M$277.00M$240.30M$258.10M$424.80M$514.50M$770.60M$867.40M$616.10M
Free Cash Flow$2.42B$2.05B$2.72B$1.27B$1.14B$3.38B$3.81B$6.56B$5.42B$3.68B$3.97B
Share Repurchasesn/an/a$0$0$750.00M$1.80B$6.68B$5.87B$4.35B$1.37B$1.00B
Shares Outstandingn/a146.80M145.80M144.90M144.00M147.00M152.40M174.20M197.20M211.50M215.90M
Weighted Average Diluted Sharesn/a147.10M145.90M145.60M146.00M149.60M161.30M187.40M205.30M213.00M218.80M
EPS (Basic)n/a$8.83$11.21$8.02$20.96$10.44$24.86$31.47$21.63$11.94$16.96

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView